Ionis Pharmaceuticals (IONS) Profit After Tax (2009 - 2026)

Ionis Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at -$114.6 million for Q2 2026.

• In Q2 2026, Profit After Tax fell 192.79% year-over-year to -$114.6 million; the TTM figure through Jun 2026 stood at -$565.2 million (down 110.72% YoY), while the FY2025 annual figure was -$381.4 million, up 15.97% from the prior year.
• Profit After Tax for Q2 2026 stood at -$114.6 million, down from -$92.5 million in the prior quarter.
• The five-year high for Profit After Tax was $123.6 million in Q2 2025, with the low at -$229.4 million in Q4 2025.
• The 5-year median for Profit After Tax is -$104.7 million (2022), against an average of -$93.2 million.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax slumped 1026.51% in 2024, then soared 286.45% in 2025.
• Ionis Pharmaceuticals' Profit After Tax stood at -$52.4 million in 2022, then soared by 82.33% to -$9.3 million in 2023, then plunged by 1026.51% to -$104.3 million in 2024, then plunged by 119.83% to -$229.4 million in 2025, then jumped by 50.02% to -$114.6 million in 2026.
• Business Quant data shows IONS's Profit After Tax at -$114.6 million in Q2 2026, -$92.5 million in Q1 2026, and -$229.4 million in Q4 2025.